SYN-004
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
ABSTRACT SYN-004 (ribaxamase) is a β-lactamase designed to be orally administered concurrently with intravenous β-lactam…
To evaluate an antibiotic inactivation strategy to protect the gut microbiome from antibiotic‐mediated damage.
Abstract Background Clostridium difficile infections (CDI) are an “urgent threat,” but there are no approved drugs or vaccines to…
P R I M A R Y E N D P O I N T C O N C L U S I O N S The use of intravenous β-lactam antibiotics, including cephalosporins, are an…
BackgroundSYN-004 is an orally administered β-lactamase enzyme, designed to be given concurrently with certain intravenous…
SYN-004 is a first in class, recombinant β-lactamase that degrades β-lactam antibiotics and has been formulated to be…
SYN-004 is a clinical stage oral β-lactamase therapy for use with intravenous (IV) β-lactam antibiotics to preserve the gut…